This episode outlines the recall of over 7,000 bottles of the antidepressant duloxetine, sold under the brand name Cymbalta, due to the presence of a potentially carcinogenic chemical, N-nitroso-duloxetine. This recall, classified as Class II by the FDA, signifies that exposure to the affected medication could result in temporary or reversible health consequences. The text advises individuals currently taking duloxetine to consult with their healthcare provider before discontinuing the medication, as sudden cessation may lead to withdrawal symptoms. The episode further elaborates on the regulatory framework governing drug recalls, highlighting the FDA's role in overseeing these processes and ensuring public safety.
This episode was brought to you by podcastworld.io an AI-powered search engine for podcasts that lets you find podcast episodes by asking questions, not just searching titles.
Here's more that you can do: